Login to Your Account

InterMune Reducing Roster By Half To Finance Pipeline

By Randall Osborne

Wednesday, March 21, 2007
In the wake of the Phase III Actimmune fizzle against idiopathic pulmonary fibrosis (IPF) about two weeks ago, InterMune Inc.'s plan to get rid of half its staff to cut costs surprised almost no one, and investors still have chips on a late-stage compound for the same indication as well as - farther back in the pipeline - a therapy for hepatitis C virus. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription